Company profile: Genelux
1.1 - Company Overview
Company description
- Provider of diagnostic and therapeutic solutions for cancer and inflammatory diseases, featuring oncolytic vaccinia virus programs: Olvi-Vec for ovarian and lung cancers (intraperitoneal or intravenous), V2ACT Immunotherapy combining oncolytic immunotherapy with adoptive cell therapy for pancreatic cancer (systemic), and V-VET1 for canine cancers (intravenous).
Products and services
- V2ACT Immunotherapy: A treatment combining oncolytic immunotherapy with adoptive cell therapy for pancreatic cancer, engineered for systemic delivery
- Olvi-Vec: A modified vaccinia virus for treating various cancer types, including ovarian and lung cancer, through delivery methods such as intraperitoneal and intravenous administration
- V-VET1: An oncolytic vaccinia virus engineered for treating canine cancers, administered intravenously using an intravenous route of administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genelux
ImmunOs Therapeutics
HQ: Switzerland
Website
- Description: Provider of next-generation human immunomodulatory therapeutics. The clinical-stage company develops IOS-1002, an immunotherapy targeting multiple immune-suppressive receptors for solid tumors and hematologic malignancies; an HLA-based platform for biologics against cancer and autoimmune diseases; and antibodies blocking specific HLA molecules for autoimmune conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunOs Therapeutics company profile →
Be Bio
HQ: United States
Website
- Description: Provider of engineered B cell medicines for serious genetic diseases, including BE-101 to produce active and sustained Factor IX for Hemophilia B. Offers BCMs engineered to produce highly active and sustained antitumor biologics for cancer, and BCMs designed to produce therapeutic proteins for genetic and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Be Bio company profile →
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Trillium Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical research and development focused on immune system regulation and the discovery and development of protein therapeutics—including monoclonal antibodies, secreted proteins, and peptides—for cancer and autoimmune indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trillium Therapeutics company profile →
Y-mAbs Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genelux
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genelux
2.2 - Growth funds investing in similar companies to Genelux
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genelux
4.2 - Public trading comparable groups for Genelux
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →